PE20240223A1 - Composiciones farmaceuticas de un inhibidor de cinasa - Google Patents
Composiciones farmaceuticas de un inhibidor de cinasaInfo
- Publication number
- PE20240223A1 PE20240223A1 PE2023001561A PE2023001561A PE20240223A1 PE 20240223 A1 PE20240223 A1 PE 20240223A1 PE 2023001561 A PE2023001561 A PE 2023001561A PE 2023001561 A PE2023001561 A PE 2023001561A PE 20240223 A1 PE20240223 A1 PE 20240223A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- composition
- pharmaceutical compositions
- kinase inhibitor
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110124P | 2020-11-05 | 2020-11-05 | |
| PCT/US2021/057996 WO2022098828A1 (en) | 2020-11-05 | 2021-11-04 | Pharmaceutical compositions of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240223A1 true PE20240223A1 (es) | 2024-02-16 |
Family
ID=78820880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001561A PE20240223A1 (es) | 2020-11-05 | 2021-11-04 | Composiciones farmaceuticas de un inhibidor de cinasa |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230398108A1 (enExample) |
| EP (1) | EP4240333A1 (enExample) |
| JP (1) | JP7879109B2 (enExample) |
| KR (1) | KR20230104186A (enExample) |
| CN (1) | CN116406261A (enExample) |
| AU (1) | AU2021374669A1 (enExample) |
| CA (1) | CA3196001A1 (enExample) |
| CL (1) | CL2023001268A1 (enExample) |
| CO (1) | CO2023005942A2 (enExample) |
| CR (1) | CR20230223A (enExample) |
| GE (1) | GEAP202316262A (enExample) |
| IL (1) | IL302485A (enExample) |
| MX (1) | MX2023005273A (enExample) |
| PE (1) | PE20240223A1 (enExample) |
| WO (1) | WO2022098828A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012009722A1 (en) * | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| ES2927651T3 (es) * | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| WO2016079687A1 (en) * | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| HRP20251184T1 (hr) | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| PL3894012T4 (pl) | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| CN116473973A (zh) * | 2018-12-24 | 2023-07-25 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 |
-
2021
- 2021-11-04 IL IL302485A patent/IL302485A/en unknown
- 2021-11-04 WO PCT/US2021/057996 patent/WO2022098828A1/en not_active Ceased
- 2021-11-04 KR KR1020237017606A patent/KR20230104186A/ko active Pending
- 2021-11-04 EP EP21819284.7A patent/EP4240333A1/en active Pending
- 2021-11-04 CA CA3196001A patent/CA3196001A1/en active Pending
- 2021-11-04 PE PE2023001561A patent/PE20240223A1/es unknown
- 2021-11-04 CN CN202180074166.6A patent/CN116406261A/zh active Pending
- 2021-11-04 MX MX2023005273A patent/MX2023005273A/es unknown
- 2021-11-04 CR CR20230223A patent/CR20230223A/es unknown
- 2021-11-04 GE GEAP202316262A patent/GEAP202316262A/en unknown
- 2021-11-04 AU AU2021374669A patent/AU2021374669A1/en active Pending
- 2021-11-04 US US18/035,355 patent/US20230398108A1/en active Pending
- 2021-11-04 JP JP2023526968A patent/JP7879109B2/ja active Active
-
2023
- 2023-05-03 CL CL2023001268A patent/CL2023001268A1/es unknown
- 2023-05-09 CO CONC2023/0005942A patent/CO2023005942A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202316262A (en) | 2023-08-10 |
| WO2022098828A1 (en) | 2022-05-12 |
| JP2023548855A (ja) | 2023-11-21 |
| IL302485A (en) | 2023-06-01 |
| CR20230223A (es) | 2023-07-07 |
| EP4240333A1 (en) | 2023-09-13 |
| MX2023005273A (es) | 2023-05-23 |
| AU2021374669A1 (en) | 2023-06-15 |
| AU2021374669A9 (en) | 2024-04-18 |
| CO2023005942A2 (es) | 2023-05-19 |
| TW202227061A (zh) | 2022-07-16 |
| US20230398108A1 (en) | 2023-12-14 |
| JP7879109B2 (ja) | 2026-06-23 |
| CL2023001268A1 (es) | 2023-12-11 |
| CN116406261A (zh) | 2023-07-07 |
| KR20230104186A (ko) | 2023-07-07 |
| CA3196001A1 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211757A1 (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| CO2021010415A2 (es) | Inhibidor jak y método de preparación del mismo | |
| ECSP20001149A (es) | Compuestos antiproliferativos y métodos para utilizarlos | |
| MX2024010045A (es) | Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas mutantes kras. | |
| MX2022014444A (es) | Sal de malato de n-(4-{[6,7-bis(metiloxi) quinolin-4-il] oxi}fenil)-n'-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer. | |
| JOP20220282A1 (ar) | مركبات مفيدة لتثبيط كيناز ret | |
| UY39027A (es) | Uso de favipiravir en el tratamiento de la infección por coronavirus | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| BR112022008786A2 (pt) | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| PE20220962A1 (es) | Formas de sales cristalinas de un inhibidor de cinasas | |
| PE20161170A1 (es) | Composiciones farmaceuticas que comprenden azd9291 | |
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| NZ607794A (en) | N-acylsulfonamide apoptosis promoters | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CU20170026A7 (es) | Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf | |
| AR058338A1 (es) | Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa. | |
| BR112018010650A8 (pt) | pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal | |
| BRPI0618479A2 (pt) | pirrolpiridinas composição farmacêutica que as contém | |
| CL2024001481A1 (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| MX2019002121A (es) | Tratamiento conjunto para tratar el cancer de pancreas. | |
| MX2024011179A (es) | Compuestos multiciclicos | |
| AR126849A1 (es) | Compuestos de quinazolina para tratamiento de enfermedad |